1
|
|
2
|
|
3
|
Draijer R, Volger OL, Dahlmans VEH, de Wit ECM, Havekes LM, Princen HMG. HOE 402 lowers serum cholesterol levels by reducing VLDL-lipid production, and not by induction of the LDL receptor, and reduces atherosclerosis in wild-type and LDL receptor-deficient mice. Biochem Pharmacol 2002; 63:1755-61. [PMID: 12007578 DOI: 10.1016/s0006-2952(02)00898-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Previous rodent studies suggested that the potent hypolipidemic agent 4-amino-2-(4,4-dimethyl-2-oxo-1-imidazolidinyl)pyrimidine-5-N-(trifluoromethyl-phenyl) carboxamide monohydrochloride (HOE 402) is an inducer of the LDL receptor (LDLR). Using wild-type and heterozygous and homozygous LDLR-deficient (LDLR+/0 and LDLR0/0) mice, fed a low or high cholesterol diet, we investigated whether HOE 402 specifically induces the LDLR and whether other pathways are affected. Upon treatment with 0.05% (w/w) HOE 402, the serum cholesterol levels of wild-type, LDLR+/0 and LDLR0/0 mice, were maximally reduced by 53, 56, and 73%, respectively (P<0.05), by reducing levels in very low density-lipoprotein (VLDL), intermediate density-lipoprotein (IDL), and low density-lipoprotein (LDL) cholesterol, whereas high density-lipoprotein (HDL) cholesterol levels were increased. The observations that HOE 402 exhibited no effect on in vivo clearance of 125I-labeled LDL in wild-type mice, and clearly reduced serum cholesterol levels in LDLR0/0 mice, indicate that the LDLR is not the main target for the compound. In wild-type mice, production of VLDL-TG, and cholesterol were reduced by more than 50% by HOE 402 (P<0.05), whereas VLDL apolipoprotein B (ApoB) secretion was unaffected, indicating that HOE 402 treatment changes the size, rather than the number of the secreted VLDL particles. The reduced VLDL production was accompanied by a 22% decreased hepatic cholesterol ester concentration (P<0.05). Additionally, HOE 402 treatment strongly reduced the aortic content of atherosclerotic lesions by 90 and 72% in LDLR+/0 and LDLR0/0 mice, respectively (P<0.01). In conclusion, HOE 402 is a potent cholesterol-lowering compound, which inhibits VLDL production, and consequently attenuates atherosclerosis development.
Collapse
Affiliation(s)
- Richard Draijer
- Gaubius Laboratory, TNO Prevention and Health, Leiden, The Netherlands
| | | | | | | | | | | |
Collapse
|
4
|
Scharnagl H, Schliack M, Löser R, Nauck M, Gierens H, Jeck N, Wieland H, Gross W, März W. The effects of lifibrol (K12.148) on the cholesterol metabolism of cultured cells: evidence for sterol independent stimulation of the LDL receptor pathway. Atherosclerosis 2000; 153:69-80. [PMID: 11058701 DOI: 10.1016/s0021-9150(00)00405-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
Lifibrol (4-(4'-tert. butylphenyl)-1-(4'-carboxyphenoxy)-2-butanol) is a new hypocholesterolemic compound; it effectively lowers low density lipoprotein (LDL) cholesterol. We studied the effects of lifibrol on the cholesterol metabolism of cultured cells. In the hepatoma cell line HepG2, Lifibrol decreased the formation of sterols from [14C]-acetic acid by approximately 25%. Similar to lovastatin, lifibrol had no effect on the synthesis of sterols from [14C]-mevalonic acid. Lifibrol did not inhibit 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. Instead, cholesterol synthesis inhibition by lifibrol was entirely accounted for by competitive inhibition of HMG-CoA synthase. Lifibrol enhanced the cellular binding, uptake, and degradation of LDL in cultured cells in a dose dependent fashion. The stimulation of LDL receptors was significantly stronger than expected from the effect of lifibrol on sterol synthesis. In parallel, lifibrol increased the amount of immunologically detectable receptor protein. Stimulation of LDL receptor mediated endocytosis was observed both in the presence and in the absence of cholesterol-containing lipoproteins. In the absence of an extracellular source of cholesterol, both lifibrol and lovastatin induced microsomal HMG-CoA reductase. Co-incubation with LDL was sufficient to suppress the lifibrol mediated increase in reductase activity, indicating that lifibrol does not affect the production of the non-sterol derivative(s) which are thought to regulate HMG-CoA reductase activity at the post-transcriptional level. Considered together, the data suggest that the hypolipidemic action of lifibrol may, at least in part, be mediated by sterol-independent stimulation of the LDL receptor pathway. A potential advantage of lifibrol is that therapeutic concentrations do not interfere with the production of mevalonate which is required not only to synthesize sterols but also as a precursor of electron transport moieties, glycoproteins and farnesylated proteins.
Collapse
Affiliation(s)
- H Scharnagl
- Department of Medicine, Divison of Clinical Chemistry, Albert Ludwigs-University, Hugstetter Strasse 55, 79106, Freiburg, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Abstract
The new therapeutic options available to clinicians treating dyslipidaemia in the last decade have enabled effective treatment for many patients. The development of the HMG-CoA reductase inhibitors (statins) have been a major advance in that they possess multiple pharmacological effects (pleiotropic effects) resulting in potent reductions of low density lipoproteins (LDL) and prevention of the atherosclerotic process. More recently, the newer fibric acid derivatives have also reduced LDL to levels comparable to those achieved with statins, have reduced triglycerides, and gemfibrozil has been shown to increase high density lipoprotein (HDL) levels. Nicotinic acid has been made tolerable with sustained-release formulations, and is still considered an excellent choice in elevating HDL cholesterol and is potentially effective in reducing lipoprotein(a) [Lp(a)] levels, an emerging risk factor for coronary heart disease (CHD). Furthermore, recent studies have reported positive lipid-lowering effects from estrogen and/or progestogen in postmenopausal women but there are still conflicting reports on the use of these agents in dyslipidaemia and in females at risk for CHD. In addition to lowering lipid levels, these antihyperlipidaemic agents may have directly or indirectly targeted thrombogenic, fibrinolytic and atherosclerotic processes which may have been unaccounted for in their overall success in clinical trials. Although LDL cholesterol is still the major target for therapy, it is likely that over the next several years other lipid/lipoprotein and nonlipid parameters will become more generally accepted targets for specific therapeutic interventions. Some important emerging lipid/lipoprotein parameters that have been associated with CHD include elevated triglyceride, oxidised LDL cholesterol and Lp(a) levels, and low HDL levels. The nonlipid parameters include elevated homocysteine and fibrinogen, and decreased endothelial-derived nitric oxide production. Among the new investigational agents are inhibitors of squalene synthetase, acylCoA: cholesterol acyltransferase, cholesteryl ester transfer protein, monocyte-macrophages and LDL cholesterol oxidation. Future applications may include thyromimetic therapy, cholesterol vaccination, somatic gene therapy, and recombinant proteins, in particular, apolipoproteins A-I and E. Non-LDL-related targets such as peroxisome proliferator-activating receptors, matrix metalloproteinases and scavenger receptor class B type I may also have clinical significance in the treatment of atherosclerosis in the near future. Before lipid-lowering therapy, dietary and lifestyle modification is and should be the first therapeutic intervention in the management of dyslipidaemia. Although current recommendations from the US and Europe are slightly different, adherence to these recommendations is essential to lower the risk of atherosclerotic vascular disease, more specifically CHD. New guidelines that are expected in the near future will encompass global opinions from the expert scientific community addressing the issue of target LDL goal (aggressive versus moderate lowering) and the application of therapy for newer emerging CHD risk factors.
Collapse
Affiliation(s)
- P H Chong
- College of Pharmacy, University of Illinois, and Cook County Hospital, Chicago 60612-3785, USA.
| | | |
Collapse
|
6
|
Murakami S, Nitanai I, Uchida S, Kondo-Ohta Y, Asami Y, Kondo K, Sato M, Kawashima A, Hara H, Tomisawa K, Mei HB, Xiang CZ. Up-regulation of low density lipoprotein receptor by a novel isobenzofranone derivative, MD-700. Atherosclerosis 1999; 146:281-90. [PMID: 10532684 DOI: 10.1016/s0021-9150(99)00148-3] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Stimulatory effects of a novel isobenzofranone, MD-700, on low density lipoprotein (LDL) receptor activity were investigated in vitro and in vivo. MD-700 at 0.03 microg/ml elevated the expression of LDL receptor in HepG2 cells within 4 h. Corresponding to this, uptake of fluorescent labeled-LDL (3,3'-dioctadecylindocarbocyanine-LDL) by the cells increased linearly in time- and dose-dependent manner by MD-700 for up to 12 h. In the experiment using HepG2 cells transiently transfected with promoter-luciferase gene constructs, MD-700 increased luciferase activity in a dose-dependent manner from 0.03 to 0.1 microg/ml. In contrast, luciferase activity was not stimulated by MD-700 in construct with a deleted sterol regulatory element (SRE)-1, suggesting importance of SRE-1 in stimulation of the LDL receptor gene promoter by MD-700. Binding experiments on liver membranes from MD-700-treated hamsters showed about a 60% increase in 125I-labeled LDL binding. A Scatchard plot revealed that MD-700 increased the maximal binding without affecting binding affinity. In contrast to findings with an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, pravastatin, MD-700 had no effect on the sterol synthesis in hamster liver homogenates. These results suggest that MD-700 stimulates the expression of LDL receptor, presumably in a manner independent of change in sterol metabolism, and thereby promotes LDL clearance. Hypocholesterolemic actions of MD-700 in hamsters were then examined. MD-700 lowered serum cholesterol levels in hamsters fed normal chow or a high-fat diet. Fractionation of serum lipoproteins demonstrated that MD-700 selectively decreased LDL and very low density lipoprotein cholesterol. Dose-dependent decrease in serum cholesterol was also seen in hypercholesterolemic rats. Thus, the hypocholesterolemic action of MD-700 may be attributed to up-regulation of the LDL receptor, based on stimulation of the transcription of the LDL receptor gene. Although pravastatin stimulates LDL uptake and lowers serum cholesterol in a manner similar to that seen with MD-700, the mechanism responsible for hypocholesterolemic action appears to differ.
Collapse
MESH Headings
- Animals
- Benzofurans/pharmacology
- Blotting, Northern
- Carbocyanines/metabolism
- Carcinoma, Hepatocellular/metabolism
- Carcinoma, Hepatocellular/pathology
- Cell Membrane/metabolism
- Cholesterol/biosynthesis
- Cricetinae
- DNA Primers/chemistry
- Disease Models, Animal
- Fluorescent Dyes/metabolism
- Humans
- Hypercholesterolemia/genetics
- Hypercholesterolemia/metabolism
- Hypercholesterolemia/pathology
- Lipoproteins, LDL/drug effects
- Lipoproteins, LDL/metabolism
- Lipoproteins, VLDL/drug effects
- Lipoproteins, VLDL/metabolism
- Liver Neoplasms/metabolism
- Liver Neoplasms/pathology
- Male
- Promoter Regions, Genetic/drug effects
- RNA, Messenger/genetics
- RNA, Neoplasm/genetics
- Rats
- Rats, Wistar
- Receptors, LDL/genetics
- Receptors, LDL/metabolism
- Sterols/metabolism
- Transcription, Genetic/drug effects
- Tumor Cells, Cultured
- Up-Regulation
Collapse
Affiliation(s)
- S Murakami
- Medicinal Research Laboratories, Taisho Pharmaceutical Co. Ltd., Ohmiya, Japan.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Ashton MJ, Jaye MC, Mason JS. New perspectives in lead generation II: Evaluating molecular diversity. Drug Discov Today 1996. [DOI: 10.1016/1359-6446(96)89091-x] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
8
|
Hoffmann A, Schmalz M, Leineweber M. Cholesterol lowering action of HOE 402 in the normolipidemic and hypercholesterolemic golden Syrian hamster. BIOCHIMICA ET BIOPHYSICA ACTA 1996; 1299:95-102. [PMID: 8555258 DOI: 10.1016/0005-2760(95)00201-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The potent hypolipidemic activity of HOE 402 (4-amino-2-(4, 4-dimethyl-2-oxo-1-imidazolidinyl)pyrimidine-5-N-(trifluoromethyl-phenyl ) carboxamide monohydrochloride), which was previously demonstrated in rat and rabbit, was investigated in noncholesterol and cholesterol fed male hamsters. In normolipidemic hamsters fed a low cholesterol chow diet containing 0.10% or 0.15% HOE 402 for 3 weeks, the plasma total cholesterol level fell by 13% and 20% respectively, but no effect on hepatic total cholesterol content was detected. Hepatic sterol synthesis was increased 3-fold in hamsters fed 0.15% HOE 402. In hamsters fed a chow diet containing 0.25% cholesterol for 3 weeks, the plasma cholesterol level increased to 226 mg/dl (compared to 123 mg/dl in their chow fed controls) and the liver cholesterol content was 26.2 mg/g compared to 2.3 mg/g in the control group. However, 0.15% HOE 402 led to a 48% reduction and 0.20% HOE 402 to a 80% reduction, in total hepatic cholesterol concentration. There was a 43% fall in plasma cholesterol level being observed with the higher HOE 402 dose. Using the dual isotope plasma ratio method, no inhibition of intestinal cholesterol absorption by HOE 402 was found, either in the noncholesterol fed or in the cholesterol fed hamsters. Cholesterol feeding diminished the whole LDL animal clearance to 393 +/- 17 microliters/h per 100 g animal (control 666 +/- 81 microliters/h per 100 g). When treated with 0.20% HOE 402, the whole animal LDL clearance rate was enhanced 2.3-fold to 824 +/- 66 microliters/h per 100 g. In the hamsters fed 0.25% cholesterol alone whole liver LDL receptor activity was suppressed to 63 +/- 5%, compared to that in the untreated controls (100%). The addition of 0.20% HOE 402 to the cholesterol enriched diet not only reversed this suppression, but resulted in a marked stimulation of liver receptor activity to 165 +/- 15% (whole body LDL receptor activity 141 +/- 10%). These results indicate that HOE 402 exerts its lipid lowering effect by a more direct activation on hepatic LDL receptor activity rather than by an indirect intestinal effect on cholesterol absorption.
Collapse
Affiliation(s)
- A Hoffmann
- Hoechst AG, Pharma Research/H 825, Frankfurt/M, Germany
| | | | | |
Collapse
|
9
|
Abstract
The effectiveness of plasma lipid lowering in the clinic is well supported by a growing number of contributions, indicating the significant improvement in cardiovascular risk in primary and particularly in secondary prevention. While these studies have clearly indicated that the more potent agents for cholesterol reduction can provide a very effective help, other pathways of lipid metabolism have gained interest. These should be evaluated, in the hope of providing a more complete answer to the question of regulating lipid absorption, distribution, and tissue deposition. In addition to newer more potent systemic lipid-lowering drugs (in particular hydroxymethylglutaryl coenzyme A reductase inhibitors), nonsystemic agents, including cholesterol sequestrants, are receiving attention. Some of these are effective at low concentrations, thus providing a potentially powerful tool for plasma cholesterol regulation. Another area of development is that of acyl coenzyme A cholesterol acyltransferase inhibitors, i.e., drugs interfering with cholesterol esterification in tissues, particularly in the arterial wall; the major problem with these seems to be that of poor tolerability and of lack of definitive proof of plasma cholesterol reduction in humans. At present, drugs for the treatment of elevated lipoprotein(a) levels are not available, with few exceptions; in this case, a better understanding of the regulation of lipoprotein(a) metabolism and of the potential benefit of treatment seems necessary. Elevation of congenitally low high density lipoprotein cholesterol levels may also be an important target: microsomal enzyme inducers have been tested, but have not provided a clinically significant response; drugs with a mixed endocrine-hypolipidemic activity possibly may prove effective. Other targets, e.g., the correction of the lipoprotein pattern characterized by "small low density lipoprotein," and the development of drugs specifically acting on the cholesteryl ester transfer protein and lipoprotein lipase systems, are being explored. Finally, new areas of development are in recombinant apolipoproteins (apo's) and in gene therapy. One case, i.e., that of apo A-I/HDL, is entering the clinical field; the mutant apo A-IMilano might provide help because of a combined cholesterol removing/fibrinolytic activity. In the case of gene therapy, at present, data on low density lipoprotein receptor replacement are encouraging. Further options, such as gene transfer in the arterial wall to induce vascular protection/disobliteration of occlusions, are also being tested.
Collapse
Affiliation(s)
- C R Sirtori
- Center E. Grossi Paoletti, University of Milano, Italy
| |
Collapse
|